Daunorubicin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Daunorubicin and local guidelines before prescribing.
Anthracycline cytotoxic
Mechanism
Anthracycline.
Uses
Acute leukaemia.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Cardiomyopathy, myelosuppression, mucositis, extravasation.
Interactions
Trastuzumab.
Contraindications and cautions
Cardiomyopathy
Monitoring
LVEF, FBC
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in renal and hepatic impairment
Overdose and reversal
Supportive
Special advice
Cumulative dose record.
More from the textbook: uses, cautions and other points
- Anthracyclines (doxorubicin, daunorubicin) - cardiotoxicity (cumulative dose - echocardiogram before and during), red urine.
Haematology: Anatomy Physiology and Pharmacology - Cytarabine + daunorubicin ("7+3") | AML induction; myelosuppression; cardiotoxicity (anthracycline).
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Induction ("7+3" - cytarabine with daunorubicin), plus targeted drugs (e.g. midostaurin for FLT3-mutated AML, gemtuzumab ozogamicin for some favourable types).
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia